Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the exercise of stock options and the same-day sale of 44,710 ordinary shares.

Key Highlights

  • Option exercise: Sabag acquired 44,710 ordinary shares on November 12, 2026, via transaction code M at an exercise price of $34.9 per share.
  • Same-day sale: The 44,710 acquired shares were sold on November 12, 2026, at a weighted average price of $44.141 per share, with individual sale prices ranging from $44.10 to $44.29, inclusive.
  • Remaining holdings: Following the transactions, Sabag directly beneficially owns 80,760 ordinary shares.
  • Options extinguished: The exercised options had been granted on February 14, 2017, and carried an expiration date of February 14, 2027; after the exercise, zero stock options remain.
  • Signing authority: The form was signed by Dov Bergwerk as attorney-in-fact for Mark Sabag.
  • Exchange and ticker: The issuer is listed as NYSE:TEVA.

Sabag Option Exercise and Share Sale at Teva Pharmaceutical

According to the Form 4 filed on November 12, 2026, Mark Sabag, identified in the filing as Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported two linked transactions in the company's ordinary shares on that same date. First, he exercised stock options (transaction code M) to acquire 44,710 ordinary shares at an exercise price of $34.9 per share, bringing his direct beneficial ownership to 125,470 shares immediately after that transaction.

In a second transaction recorded the same day, the filing disclosed that Sabag disposed of (transaction code S) all 44,710 of those newly acquired shares at a weighted average price of $44.141 per share. The filing noted that the shares "were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive," and stated that full details of the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder. After this sale, his directly held ordinary shares totaled 80,760.

The filing explained that the exercised stock options were originally granted on February 14, 2017. According to the footnote, 30,236 options vested on each of February 14, 2018, February 14, 2019, and February 14, 2020, and 30,238 options vested on February 14, 2021. The options carried an expiration date of February 14, 2027. Following the exercise, the filing reported zero stock options remaining in Sabag's direct ownership.

What Was Disclosed

The filing reported that Teva officer Mark Sabag exercised 44,710 stock options at $34.9 per share and sold the same number of ordinary shares at a weighted average of $44.141 on November 12, 2026, leaving him with 80,760 directly held ordinary shares.